



6th Annual

# CNS Drug Delivery Summit

Innovating Optimized Delivery to Specific CNS Targets

December 3 - 5, 2024 | Boston, MA

EXCLUSIVE SPEAKER INTERVIEW



**Mathias Schmidt**

Executive Advisor to the President, Chairman & CEO

**JCR Pharmaceuticals**

### How has the CNS drug delivery landscape evolved over the last 12 months and where do you see it heading in the next few years?

The big pharma industry has finally woken up to the innovation brought to the field by mid-size players: The approval of the first Biologic designed to cross the blood-brain-barrier to treat CNS sequelae of a disease (IZCARGO®; pabinafusp alfa) has completely changed the landscape.

The direction we will be heading is the application of such platforms to:

1. Create 2nd generation Alzheimer antibodies (developers understand that augmenting the hitherto limited efficacy can only be accomplished by increasing the brain penetration using a carrier technology.)
2. Use validated platforms to transport other effectors into the CNS (anti-inflammatory biologics, biologics with anti-cancer action, gene therapy for the sustained knockdown of gain-of-function mutations in brain diseases.)

### What would you say are the most promising innovations currently advancing receptor-mediated transcytosis of the blood-brain barrier?

The fact that we got the first molecule approved based on receptor-mediated transcytosis. Companies are researching on other receptors to further augment delivery to the brain.

### During your pre-conference workshop on the potential of systemic ASO delivery to the CNS, what key translational challenges do you hope to address?

While we can deliver ASOs to other tissues and organs, delivery of nucleic acid medicine is still challenging. What are the reasons for this?

### Which other sessions in the agenda are you most looking forward to at the 6th CNS Drug Delivery Summit?

Day 2 – updates on clinical programs.

# Download your copy of the full program



[www.cns-drug-delivery.com](http://www.cns-drug-delivery.com)

T +1 617 455 4188 E [info@hansonwade.com](mailto:info@hansonwade.com)

